We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




Novel Hemostatic Immunoassay Detects VTE with Excellent Accuracy, Reliability and Turnaround Time

By LabMedica International staff writers
Posted on 10 May 2022

D-dimer measurement is one of the most commonly requested tests in the hemostasis laboratory and is frequently used to exclude venous thromboembolism (VTE). More...

While a number of different immunoturbidimetric assays for D-dimer are marketed for routine practice, their reliability and analytical performance can vary. Now, scientists have successfully evaluated the analytical performance of a novel hemostatic immunoassay and demonstrated it to detect VTE with excellent accuracy, reliability and turnaround time.

The independent study compared the performance of Horiba Medical’s (Kyoto, Japan) Yumizen G DDi 2 assay, designed for its Yumizen G hemostasis analyzer range, versus other available immunoturbidimetric D-dimer assays. The study analyzed the precision of Yumizen G DDi 2 by running repeat assays with a standardized control sample and found its coefficient of variation to fall within an ideal range for diagnostic purposes. The lower and upper detection limits of the Yumizen G DDi 2 assay were comparable to other D-dimer immunoassays tested, and notably it excelled in assay linearity, which was found to be maintained for a broad range of concentrations. The calculated linear range (up to 32700ng/mL FEU) extended significantly further than that specified by HORIBA (up to 20000ng/mL FEU). This makes the Yumizen G DDi 2 assay ideal for the direct measurement of most clinical samples without need for manual dilution steps, therefore decreasing sample turnaround time.

D-dimer immunoassays can often be marred by interference from hemolysis, icterus and lipemia, or heterophilic antibodies such as HAMAs and RF, and the study evaluated the Yumizen G DDi 2 assay for each. No significant impact of hemolysis was found for hemoglobin concentrations up to 10g/L, which was greater than other D-dimer assays. In addition, no interference of HAMAs (up to 500ng/mL) and RF (up to 935UI/mL) was detected. Since RF levels rarely exceed 1000UI/mL in clinical practice, the safety of the Yumizen G DDi 2 assay was strengthened further.

HORIBA’s Yumizen G DDi reagent kit is available for its comprehensive range of Yumizen G hemostasis instruments which covers the needs of any laboratory. The dedicated coagulation portfolio includes the fully automatic Yumizen G800, Yumizen G1500 and Yumizen G1550, as well as semi-automatic Yumizen G200 and Yumizen G400 analyzers. Using antibody-coated latex particles and measured via the immunoturbidimetric channels of these Yumizen G hemostasis instruments, HORIBA’s reagent kit delivers D-dimer results consistency and analytical performance reliability as demonstrated by the recent evaluation study.

Related Links:
Horiba Medical 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.